PGC-1α activity and mitochondrial dysfunction in preterm infants.

Area of Science:

• Neonatal Medicine
• Mitochondrial Biology
• Developmental Pediatrics

Background:

• Extremely low gestational age neonates (ELGANs) are susceptible to hyperoxia and oxidative stress, leading to mitochondrial dysfunction.
• Mitochondrial dysfunction in neonates significantly impacts the brain and lungs, contributing to white matter injury (WMI) and bronchopulmonary dysplasia (BPD).
• Proper mitochondrial function is crucial for organ development, energy production, and mitigating oxidative stress via reactive oxygen species (ROS) and reactive nitrogen species (RNS).

Purpose of the Study:

• To review therapeutic agents that modulate mitochondrial function by targeting the PGC-1α pathway.
• To explore the potential of PGC-1α activators in mitigating WMI and BPD in ELGANs.
• To identify promising candidates for further pre-clinical and clinical investigation.

Main Methods:

• Literature review of therapeutic agents impacting PGC-1α.
• Analysis of PGC-1α's role in mitochondrial biogenesis and function.
• Identification of agents that activate or upregulate PGC-1α.

Main Results:

• Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) is a key regulator of mitochondrial health.
• Several agents, including metformin, resveratrol, omega-3 fatty acids, montelukast, L-citrulline, and adiponectin, show potential for PGC-1α pathway modulation.
• These agents may mitigate mitochondrial dysfunction underlying WMI and BPD.

Conclusions:

• Targeting the PGC-1α pathway represents a promising therapeutic strategy for neonatal mitochondrial dysfunction.
• Metformin, resveratrol, and other agents warrant further investigation for their efficacy in preventing WMI and BPD in preterm infants.
• Understanding PGC-1α's role is critical for developing novel treatments to improve outcomes for ELGANs.